Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy Virtual 2020 | Targeting SLAMF7 in myeloma

Katja Weisel, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, discusses elotuzumab, a monoclonal antibody targeting SLAMF7, in relapsed/refractory multiple myeloma. Additionally, Dr Weisel reveals that SLAMF7 is an important target for CAR T-cell therapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).